Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Urinary frequency)
70,609 results
  • Persistent muscle invasive bladder cancer after neoadjuvant chemotherapy: An analysis of SEER-Medicare data. [Journal Article]
  • BIBJU Int 2018 Aug 20
  • Lane G, Risk M, … Konety B
  • CONCLUSIONS: Patients who have persistent muscle invasive bladder cancer after platinum-based NAC+RC vs RC alone derive an OS benefit but not a CSS benefit from NAC. This may represent a selection bias favoring patients who are selected for NAC. However, the OS benefit is not evident in patients with persistent pT3-T4N0M0 disease. This study underscores the importance of future research investigating methods to identify patients who will respond to NAC for bladder cancer. It is also highlights the need to consider adjuvant therapy in patients who have persistent MIBC after NAC. This article is protected by copyright. All rights reserved.
New Search Next